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We examined the risk of cancer and survival in a cohort of patients hospitalised with herpes zoster between 1977 and 1996, drawn
from the Danish National Registry of Patients. Through linkage with the Danish Cancer Registry, we compared the observed number
of cancers with the expected number on the basis of national age-, gender-, and site-specific incidence rates. The survival of herpes
zoster patients with cancer was compared with that of non-herpes zoster patients with cancer. Among the 10588 patients
hospitalised with herpes zoster whom we identified, 1427 cancers were observed compared with 1239 expected (relative risk¼1.2,
95% confidence interval 1.1–1.2). The risk was substantially elevated during the first year of follow-up, mainly for haematological
cancer. Patients with cancer within 1 year of follow-up had a higher prevalence of distant metastases than controls, although the
mortality was similar. For those with haematological cancer, however, the mortality was higher for herpes zoster patients than for
controls. Haematological cancer following hospitalisation for herpes zoster has a poorer prognosis than in non-herpes zoster patients.
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Herpes zoster occurs frequently in immunocompromised patients,
such as the elderly and those with lymphoproliferative malig-
nancies, AIDS, and in transplant recipients (Dolin et al, 1978;
Mazur and Dolin, 1978; Freidman-Kien et al, 1986; Melbye et al,
1987; Donahue et al, 1995; Poulsen et al, 1996; Gnann and Richard,
2002). An association between cancer and herpes zoster has been
recognised since 1955 (Wyburn-Mason, 1955), and it has been
hypothesised that herpes zoster may be a predictor of a subsequent
diagnosis of cancer (Smith and Fenske, 1995). Case reports have
suggested such an association (Wright and Winer, 1961; Muller,
1967; Cohen et al, 1984), but only three relatively small studies
have prospectively examined the risk of malignancy subsequent to
herpes zoster, and these found no significantly increased risk
(Ragozzino et al, 1982; Fueyo and Lookingbill, 1984; Wurzel et al,
1986). Other studies have examined this association, but most of
them were based on patients with prevalent cancer, did not include
controls, or were unable to disentangle the temporal relationship
(Wyburn-Mason, 1955; McGregor, 1957; de Moragas and Kierland,
1957; Wright and Winer, 1961; Merselis et al, 1963; Muller, 1967;
Rogers and Tindall, 1971; Schimpff et al, 1972; Brown, 1976). In
addition, little is known about the prognosis of patients with
cancer discovered after hospitalisation with herpes zoster.
To assess the herpes zoster–cancer association without such
limitations, we determined the risk of cancer after hospitalisation
for herpes zoster, as well as the prognosis of such cancers, using
nationwide population-based data from the Danish Registry of
Patients and the Danish Cancer Registry.
METHODS
The Danish National Registry of Patients was established in 1977,
and 99.4% of all discharges from Danish nonpsychiatric hospital
departments are recorded there (Andersen et al, 1999). Recorded
information includes the civil registration number, the dates of
admission and discharge, the surgical procedures performed, and
up to 20 discharge diagnoses. The National Health Service provides
tax-supported free medical care to all Danish citizens. The civil
registration number, which is unique to every Danish citizen,
permits accurate linkage of information among registers. Dis-
charge diagnoses were coded according to the Danish version of
the International Classification of Diseases, 8th revision (ICD-8),
until 31 December 1993, and according to the 10th revision
thereafter (Andersen et al, 1999).
All hospitalisations for herpes zoster (ICD-8 codes 053.00–
053.9 and ICD-10 codes B02.0-B02.9) from 1 January 1977 to
31 December 1996 were extracted from the National Registry of
Patients. We identified 13414 patients hospitalised with herpes
zoster and obtained their full hospitalisation history. This led to
the exclusion of 402 patients who had received an organ
transplantation before the diagnosis of herpes zoster or were
diagnosed with human immunodeficiency virus at any time
during the study period, and 2026 patients with a cancer
diagnosis prior to or within 2 months after the diagnosis of
herpes zoster.
The remaining 10986 herpes zoster patients were linked to the
Central Population Registry for verification of the civil registration
number and for information on vital status and emigration. This
led to the exclusion of 398 patients who died during the
hospitalisation for herpes zoster or had an erroneous registration.
The resulting 10588 eligible herpes zoster patients were classified
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yin two ways on the basis of ICD codes: (1) into 7434 patients with
uncomplicated herpes zoster and 3154 patients with complicated
herpes zoster; and (2) into 392 patients with disseminated herpes
zoster and 10196 patients with localised herpes zoster.
The 10588 herpes zoster patients were followed for cancer
occurrence from 2 months after the date of discharge with a first
time diagnosis of herpes zoster to be certain that the zoster
diagnosis came before the cancer diagnosis until (1) the date of
death or emigration, identified through the Central Population
Registry, (2) a diagnosis of organ transplantation or primary
immune deficiency, identified through the National Registry of
Patients, or (3) until 31 December 1998, whichever came first.
Information on cancer occurrence was obtained through record
linkage to the Danish Cancer Registry with records of all incident
cases of cancer in Denmark since 1943. Cancers are classified
according to the modified Danish version of the International
Classification of Diseases, 7th revision (Storm et al, 1997). The
registration is based on notification forms that are completed by
hospital departments (including departments of pathology and
forensic medicine) and practicing physicians whenever a case of
cancer is diagnosed or found at autopsy, and whenever changes to
the initial diagnosis are made. The cases thus reported manually
are supplemented by cases revealed by the computerised linkages
to the death certificate file and the National Registry of Patients.
Ambiguous or contradictory information, either within a notifica-
tion form or between forms, leads to requests for clarification in
approximately 10% of notifications received. Comprehensive
validation has shown that the Registry is 95–98% complete and
valid (Andersen et al, 1999).
Through the Cancer Registry, we aimed to identify a control
group of up to 10 cancer patients without herpes zoster for each
herpes zoster patient with cancer. Controls were matched on
cancer type, gender, age in 10-year age groups, and calendar year
of diagnosis in 5-year periods. However, we were unable to identify
10 matching patients for each herpes zoster patient with cancer, so
the control group comprised only 12193 patients.
Statistical analysis
The expected number of cancers was calculated on the basis of
Danish national incidence rates for primary cancers according to
gender, age, and calendar time in 5-year intervals. Multiplying the
number of person-years under observation by the appropriate
cancer incidence rates yielded the number of cancers that would be
expected if patients with herpes zoster had the same risk of cancer
as that of the general population. Confidence intervals (CIs) for the
standardised incidence ratio – that is, the relative risk, calculated
as the ratio of observed to expected cancers – were based on the
assumption that the observed number of cases in a specific
category follows a Poisson distribution. We examined the
association between herpes zoster and all cancer types combined,
as well as the association between herpes zoster and haematolo-
gical cancers, cancers associated with immunosuppression (Nasca,
2001), and other cancers.
Through the Danish Cancer Registry, we obtained information
on the extent of cancer spread among the herpes zoster patients
who developed cancer during follow-up (cases). The extent of
spread was divided into ‘no spread,’ ‘regional spread’, and ‘distant
metastases’. We calculated the prevalence ratio of distant
metastases (the proportion of cases with distant metastases
divided by the proportion of controls with distant metastases)
and an associated 95% CI.
We used proportional hazards regression analyses to compare
the risk of death after a cancer diagnosis for cases relative to that
for controls. We did separate analyses on cases with haematolo-
gical cancer and those with other types of cancer. The comparisons
were based on estimation of mortality ratios and associated 95%
CI. All statistical analyses were performed with Stata software
(Stata Corporation, Texas, USA).
RESULTS
The 10588 herpes zoster patients in the study (3972 men and 6616
women), were followed for 75774 person-years yielding an average
length of follow-up of 7.2 years. The median age at first
hospitalisation for herpes zoster was 72 years.
Cancer risk
We found a total of 1427 cases of cancer with 1239 expected,
yielding an overall relative risk of 1.2. (95% CI 1.1–1.2). The
relative risks were the same in men and women (data not shown),
and did not depend on the year of herpes zoster diagnosis (data
not shown).
In the first year of follow-up, 188 cancers were identified,
yielding a cumulative cancer risk of 1.8%. Of the 188 cancers, 29
(15%) were haematological cancers, yielding a cumulative risk of
haematological cancer of 0.3%. The overall relative risk of a
diagnosis of cancer during the first year of follow-up was 1.3 (95%
CI 1.1–1.5) and did not vary with the year of hospitalisation. In the
first year of follow-up, we found a particularly high risk for
haematological cancer with a relative risk of 3.4 (95% CI 2.3–4.9)
(Table 1).
The relative risk of haematological cancer (Hodgkin’s disease,
non-Hodgkin’s lymphoma, multiple myeloma, and leukaemia)
varied with time of follow-up after the herpes zoster diagnosis
(Tables 1 and 2), so that it was 4.0 (95% CI 1.3–9.3) in the first 3
months, 3.2 (95% CI 1.4–6.4) between 3 and 6 months, 4.6 (95% CI
2.3–8.2) between 6 and 9 months, 2.1 (95% CI 0.7–4.9) between 9
Table 1 Relative risk (RR) for selected cancers within the first year of
follow-up among patients previously hospitalised for herpes zoster; follow-
up started 2 months after the date of discharge with herpes zoster
Observed RR 95% CI
a
All malignant neoplasms 188 1.3 1.1–1.5
Haematological cancers 29 3.4 2.3–4.9
Non-Hodgkin’s lymphoma
b 11 3.8 1.9–6.7
Hodgkin’s lymphoma 0 — —
Multiple myeloma 8 4.8 2.1–9.4
Leukaemia 10 2.8 1.3–5.1
Immune-related cancers 32 1.1 0.8–1.6
Liver 3 1.5 0.4–6.0
Cervix 1 0.5 0.01–2.5
Nonmelanoma skin cancer 24 1.1 0.7–1.7
Malignant melanoma 1 0.5 0.01–2.5
Sarcoma
c 3 2.7 0.6–7.8
All other sites
d 127 1.2 1.0–1.4
Brain 0 — —
Oesophagus 2 1.3 0.2–5.4
Stomach 6 1.1 0.4–2.3
Colon 12 0.8 0.4–1.4
Rectum 7 1.0 0.4–2.0
Pancreas 6 1.3 0.5–2.7
Lung 22 1.4 0.9–2.2
Breast 12 0.8 0.4–1.4
Corpus uteri 3 0.9 0.2–2.6
Ovary 7 2.3 0.9–4.8
Prostate 14 1.4 0.8–2.4
Kidney 6 1.7 0.6–3.8
Bladder 12 1.4 0.8–2.5
aCI denotes confidence interval.
bNon-Hodgkin’s lymphoma is also classified as an
immune-related cancer.
cAmong sarcomas, only Kaposi’s sarcoma is regarded as an
immune-related cancer.
dOnly selected sites are specified.
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(95% CI 0.9–1.9) between 5 and 10 years, and 1.7 (95% CI 1.1–2.6)
after more than 10 years. The relative risks of nonhaematological
cancer in the same periods were 1.7 (95% CI 1.2–2.4), 1.5 (95% CI
1.1–1.9), 0.9 (95% CI 0.6–1.3), 0.8 (95% CI 0.5–1.1), 1.1 (95% CI
1.0–1.2), 1.1 (95% CI 1.0–1.2), and 1.1 (95% CI 1.0–1.3),
respectively.
For patients with uncomplicated herpes zoster, the relative risk
of any cancer during the first year of follow-up was 1.4 (95% CI
1.2–1.6), whereas it was 1.1 (95% CI 0.8–1.5) for patients with
complicated herpes zoster. For patients with disseminated herpes
zoster, it was 1.5 (95% CI 0.7–2.8), and it was 1.3 (95% CI 1.1–1.5)
for patients with other localised herpes zoster.
Cancer extent and prognosis
Because we were unable to identify matching patients for all 1382
herpes zoster patients with cancer, only 1341 (97%) of these
patients were included in the analyses of extent of cancer and of
survival after the cancer diagnosis. We had information on the
extent of cancer at the time of diagnosis in 79% of cases and 81%
of controls. Among those cases who developed cancer within the
first year after hospitalisation for herpes zoster, the prevalence
ratio of distant spread was higher among the herpes zoster patients
than among the controls (prevalence ratio 1.27; 95% CI 0.99–1.63),
whereas it was close to unity among those who developed cancer
more than 1 year after hospitalisation for herpes zoster (prevalence
ratio 1.07; 95% CI 0.92–1.23) (Table 3).
The survival curves for herpes zoster patients in whom cancer
was diagnosed within the first year after herpes zoster hospitalisa-
tion, and their matched controls, were almost similar with a
mortality ratio of 1.02 (95% CI 0.85–1.22). For cases with
haematological cancer, however, the mortality ratio was 1.38
(95% CI 0.83–2.28), whereas that for cases with nonhaematological
cancer was 0.98 (95% CI 0.84–1.19) (Figure 1).
The survival curve for herpes zoster patients in whom cancer
was diagnosed more than 1 year after the herpes zoster
hospitalisation was similar to that for their matched controls.
The mortality ratio was 1.03 (95% CI 0.96–1.11). For cases with
haematological cancer, the survival curves for cases and their
controls were only slightly different with a mortality ratio of 1.11
(95% CI 0.85–1.46), and for cases with nonhaematological cancer,
the mortality ratio was 1.02 (95% CI 0.95–1.11).
DISCUSSION
In this large, population-based, follow-up study, we found an
increased risk of several types of cancer after hospitalisation for
herpes zoster, particularly during the first year of follow-up. In
particular, there was a strong association between herpes zoster
and haematological cancers. Hospitalisation for herpes zoster was
Table 2 Relative risk (RR) for selected cancers beyond the first year of
follow-up among patients previously hospitalised for herpes zoster; follow-
up started 2 months after the date of discharge with herpes zoster
Observed RR 95% CI
a
All malignant neoplasms 1239 1.1 1.1–1.2
Haematological cancers 111 1.7 1.4–2.0
Non-Hodgkin’s lymphoma
b 38 1.6 1.1–2.2
Hodgkin’s lymphoma 6 3.0 1.1–6.6
Multiple myeloma 22 1.7 1.1–2.6
Leukaemia 45 1.7 1.2–2.2
Immune-related cancers 251 1.1 1.0–1.2
Liver 13 1.3 0.7–2.2
Cervix 11 0.8 0.4–1.5
Nonmelanoma skin cancer 203 1.1 1.0–1.3
Malignant melanoma 15 0.8 0.5–1.3
Sarcoma
c 9 1.1 0.5–2.1
All other sites
d 877 1.1 1.0–1.2
Brain 29 1.6 1.1–2.3
Oesophagus 16 1.5 0.9–2.4
Stomach 44 1.3 0.9–1.7
Colon 97 0.9 0.7–1.1
Rectum 48 0.9 0.7–1.2
Pancreas 39 1.2 0.8–1.6
Lung 130 1.2 1.0–1.4
Breast 127 1.1 0.9–1.3
Corpus uteri 24 1.0 0.6–1.4
Ovary 23 1.1 0.7–1.6
Prostate 79 1.2 0.9–1.4
Kidney 32 1.3 0.9–1.8
Bladder 59 1.0 0.7–1.2
aCI denotes confidence interval.
bNon-Hodgkin’s lymphoma is also classified as an
immune-related cancer.
cAmong sarcomas, only Kaposi’s sarcoma is regarded as an
immune-related cancer.
dOnly selected sites are specified.
Table 3 Extent of the spread of cancer according to the presence or absence of herpes zoster
Cancer o1 year after herpes zoster Cancer 1–21 years after herpes zoster
Patients
(N¼176)
Controls
(N¼1623)
Prevalence
ratio (95% CI
a)
Patients
(N¼1165)
Controls
(N¼10570)
Prevalence
ratio (95% CI
a)
Patients with data on spread 136 (77%) 1287 (79%) 923 (79%) 8531 (81%)
No spread 60 (44%) 607 (47%) 477 (52%) 4692 (55%)
Regional spread 29 (21%) 330 (26%) 226 (24%) 1914 (22%)
Distant metastasis 47 (35%) 350 (27%) 1.27 (0.99–1.63) 220 (24%) 1925 (23%) 1.07 (0.92–1.23)
aCI denotes confidence interval.
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Figure 1 Survival curves for patients with herpes zoster (solid lines) and
haematological cancer (black) or nonhaematological cancer (grey). Cancers
were diagnosed within the first year of follow-up. Follow-up started 2
months after the date of discharge with herpes zoster. Matched controls
are represented by dashed lines.
Cancer and herpes zoster
HT Sørensen et al
1277
British Journal of Cancer (2004) 91(7), 1275–1279 & 2004 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
yalso a marker of long-term cancer risk – even after 10 years, we
found a 1.7-fold increase in the risk of haematological cancer.
Further, patients with herpes zoster were more likely to have
advanced cancer than matched controls, although survival curves
for nonhaematological cancer were similar. For haematological
cancer, however, herpes zoster patients had a poorer survival than
their matched controls.
Our findings differ from those of the few previous studies on
this topic (Ragozzino et al, 1982; Fueyo and Lookingbill, 1984,
Wurzel et al, 1986). In aggregate, three small studies followed 662
patients. A total of 91 cancer cases were observed compared with
84 expected in the two studies with internal or external controls
(Ragozzino et al, 1982; Fueyo and Lookingbill, 1984). No cancer
cases were found in the third study of children (Wurzel et al,
1986). Consequently, these studies had neither the power to detect
a substantially increased overall cancer risk nor the ability to study
site-specific cancer risks. In addition, they had few clinical details.
There may be several reasons as to why cancer might be
associated with herpes zoster. Increased diagnostic effort could
explain the association in the short term, but it seems unlikely for
heightened surveillance to explain an increased risk many years
after the hospitalisation for herpes zoster. Moreover, there was no
compensating deficit after a time-limited period of increased risk,
and the risk differed between haematological and nonhaematolo-
gical cancers.
Confounding by smoking may explain a part of the increased
risk in the long term since we found an increased risk of many
tobacco-related cancers, and smoking, in itself, has some impact
on the immune function (Holt, 1987). One common risk factor for
both herpes zoster and cancer is cell-mediated immunity, which
likely explains the strong associations with haematological cancers.
Varicella zoster virus remains in a dormant state until the cell-
mediated immune system is depressed and allows the virus to
multiply. There is some evidence that infections may promote
certain types of cancers (Kuper et al, 2000). It has also been
suggested that herpes zoster has a direct carcinogenic effect
(Rogers and Tindall, 1971).
We found an increased long-term risk of brain tumour after
herpes zoster hospitalisation, but it is not possible to assess
whether this finding was caused by chance or unknown
confounding, or whether it reflects the tropism for the virus
towards neural tissue. However, this hypothesis was not supported
by the findings of an American case–control study in which adults
with glioma were less likely than controls to have had prior
varicella zoster virus infection or to have an immunoglobulin-G
antibody response adequate to indicate positivity (Wrensch et al,
1997, 2001).
The survival curves for herpes zoster patients with nonhaema-
tological cancer and controls were similar indicating that herpes
zoster is not associated with particularly aggressive nonhaemato-
logical cancer. For haematological cancer, on the other hand,
herpes zoster appears to be associated with more aggressive
disease, and this is similar to what has been found for other
paraneoplastic syndromes, for example, venous thromboembolism
and hypercalcaemia (Kristensen et al, 1998; Sørensen et al, 2000).
The study population was large and well defined, and the long-
term follow-up was complete, since our design used computerised
registries with complete nationwide coverage of hospitalised
patients. Consequently, our findings are limited to a population
of severe herpes zoster cases that require hospitalisation, but the
risk estimates varied only slightly with the type of herpes zoster
patients. Limitations of our study are the existence of coding errors
and the possible misclassification of the herpes zoster diagnosis in
the National Registry of Patients. If nondifferential, this problem
would reduce the strength of the associations we reported. Also, we
lacked direct information on potential confounders, such as
cigarette smoking and use of immunosuppressive drugs.
Our data clearly showed an association between hospitalisation
for herpes zoster and cancer, in contrast to previous research, and
even demonstrated a long-term association. Our data are
consistent with the hypothesis that herpes zoster may be a marker
of haematological cancers, in particular. Nonetheless, the limita-
tions of our data prevent us from suggesting guidelines for
searching for occult cancer in patients with herpes zoster. In our
cohort, patients diagnosed with cancer in the first 2 months after
herpes zoster were excluded, but it is most likely that some cancers
diagnosed in the following months were present at the time of
hospitalisation for herpes zoster. Early diagnosis of some cancers
would have required extensive work-up, and it is unclear whether
early diagnosis would have changed the outcome. Some of the
haematological cancers might be detected by simple methods, but
only 1.8% of herpes zoster patients had a cancer diagnosis within
the first year of follow-up, including 0.3% with haematological
cancer, and 35% had metastases at the time of diagnosis. These
findings suggest that cancer screening of patients hospitalised for
herpes zoster will have low efficacy.
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